Log In
Print
BCIQ
Print
Print this Print this
 

Grazax (grass pollen Allergy Immunotherapy Tablet (AIT), Grastek) (MK-7243)

Also known as: Grass pollen allergen tablet

  Manage Alerts
Collapse Summary General Information
Company ALK-Abello A/S
DescriptionTablet-based sublingual allergen immunotherapy
Molecular Target Not applicable
Mechanism of ActionImmunotherapy
Therapeutic ModalityBiologic
Latest Stage of DevelopmentMarketed
Standard IndicationAllergy
Indication DetailsPrevent development of asthma in children with allergic rhinoconjuntivitis; Treat grass pollen allergy; Treat grass pollen-induced allergic rhinoconjunctivitis (hay fever); Treat mild to moderate hay fever; Treat moderate to severe hay fever; Treat Timothy grass pollen induced allergic rhinitis, with or without conjunctivitis
Regulatory Designation
Partner Merck & Co. Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

3

$81.4M

$40.7M

$40.7M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today